Welcome to our dedicated page for KINETA news (Ticker: KANT), a resource for investors and traders seeking the latest updates and insights on KINETA stock.
The KANT news page on Stock Titan provides an archive of public announcements and press releases related to Kineta, Inc., a clinical-stage biotechnology company that focused on developing novel immunotherapies in oncology. These news items document Kineta’s work on cancer immune resistance, its VISTA-101 clinical program for the VISTA blocking antibody KVA12123, and the company’s strategic and corporate developments over time.
Readers can find coverage of Kineta’s clinical updates, including reported progress from the Phase 1/2 VISTA-101 trial in advanced solid tumors, where KVA12123 was evaluated as monotherapy and in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab). News reports describe safety and tolerability observations, dose escalation milestones, and early signals such as stable disease or partial responses in certain cohorts, as presented at conferences like the American Association for Cancer Research (AACR) and the Society for Immunotherapy of Cancer (SITC).
The news record also includes corporate announcements, such as Kineta’s February 2024 restructuring to reduce expenses and preserve cash, the subsequent exclusivity and right of first offer agreement with TuHURA Biosciences, and the definitive merger agreement under which TuHURA agreed to acquire Kineta. Later releases from TuHURA describe stockholder approvals of the merger and, ultimately, the completion of the acquisition, with KVA12123 being renamed TBS-2025 within TuHURA’s pipeline.
For investors and researchers, this news archive offers historical context on Kineta’s evolution from an independent clinical-stage biotechnology company trading under the KANT ticker to a business that has been acquired by TuHURA Biosciences. Reviewing these articles can help users understand how the VISTA-targeted antibody program advanced, how strategic alternatives were pursued, and how the merger terms and closing were communicated to the market.
Kineta, Inc. (OTC Pink: KANT) announced that TuHURA Biosciences Inc has extended their exclusivity and right of first offer agreement for Kineta's VISTA blocking antibody KVA12123. This extension is part of the agreement entered in July 2024, allowing TuHURA to extend their rights for up to two 10-day periods, with Kineta receiving $150,000 for each extension.
Kineta reopened the Phase 1 clinical study in August 2024 and is currently enrolling patients with advanced solid tumor cancers. The company aims to complete enrollment by year-end 2024. KVA12123 has shown strong tumor growth inhibition in preclinical models and may be effective for various cancer types, including NSCLC, colorectal, renal cell carcinoma, head and neck, and ovarian cancer.
Kineta continues to explore strategic alternatives to maximize shareholder value, with more information expected later this year.
Kineta, a clinical-stage biotech firm, announced its transition from Nasdaq to the OTC Pink Open Market, trading under the ticker KANT as of September 19, 2024. This move follows Nasdaq's decision to delist Kineta due to non-compliance with the $1.00 minimum bid price and $2.5 million stockholders' equity requirements. Shareholders' investments remain secure and tradable. Kineta continues its focus on strategic alternatives and its KVA12123 Phase 1 study, which is open for new patient enrollment. Additionally, Kineta has an exclusivity agreement with TuHURA Biosciences, providing a $5 million nonrefundable payment and cooperation on the VISTA-101 Phase 1/2 trial.